Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold some at $4.81 like an idiot haha
Hence why we take some off the table on any stock that is up 100% or more in one day. I do love cabbage!
However, my earlier post HERE is the TRUTH!!
Just gotta be careful with these news release " plans to explore the potential to develop a novel monkeypox vaccine "
Anytime bro.
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
August 17 2022 - 08:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform.
The Company’s S&P platform is currently being utilized to develop vaccine candidates across multiple diseases, including BWV-101 for influenza, BWV-301 for gastroenteritis via norovirus or rotavirus infection, and BWV-302 for malaria. In this new effort, BWV will attempt to present monkeypox antigens within the S&P platform to potentially create a vaccine candidate capable of protecting individuals against monkeypox disease.
“As monkeypox cases rise around the globe, BWV is committed to exploring the potential of our platform to create a novel monkeypox vaccine candidate,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. “Our VLP platform has previously demonstrated versatility across multiple infectious diseases, and we are excited to initiate this research to understand the potential to create another vaccine to fight this outbreak.”
In July 2021, Blue Water Vaccines entered an exclusive, global licensing agreement with Cincinnati Children’s to develop vaccines for multiple infectious diseases utilizing the latter’s novel virus-like particle (VLP) vaccine platform. The platform leverages norovirus capsid proteins to present foreign antigens for immune enhancement.
According to the World Health Organization, monkeypox is a virus transmitted to humans from animals, with clinical symptoms like those seen in smallpox patients. Human-to-human transmission can result from close contact with respiratory secretions, skin lesions of an infected person, or recently contaminated objects. According to the Centers for Disease Control and Prevention, there have been about 12,000 reported cases of monkeypox in the United States between May and August 2022. There are two vaccines approved for prevention of monkeypox disease in the United States, but limited availability of either vaccine has resulted in increasing cases within the US and globally.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon
Looks like it's starting to catch some steam
company website
https://www.bluewatervaccines.com
low float 12m 6x turnover today $BWV
the next Big Pharma vaccine in the making
Upcoming Shareholder's Meeting August 22
2022 Annual Meeting of Stockholders of Blue Water Vaccines Inc. (the “Company”) to be held on Monday, August 22, 2022 at 9:00 a.m. Eastern Time at the offices of Ellenoff Grossman & Schole LLP located at 1345 Avenue of the Americas, 11th Fl., New York, NY
Boy, I'll say.
Delayed reaction.
That's OLD news; so WHY is it up huge in the pre-market???
Blue Water Vaccines : Announces Signing of Sponsored Research Agreement with Cincinnati Children's Hospital Medical Center for S&P Vaccine Platform Development - Form 8-K
https://www.marketscreener.com/quote/stock/BLUE-WATER-VACCINES-INC-133576962/news/Blue-Water-Vaccines-Announces-Signing-of-Sponsored-Research-Agreement-with-Cincinnati-Children-s-H-41079126/
So far this is not a company but a share dumping machine. Do they even know how to make a vaccine?
Uoooogly chart here
7.10 > early hod.
"Our need for additional financing" > Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
8:30 am ET May 12, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:BWV), EQNX::TICKER_END Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company") a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer of Blue Water Vaccines, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand webcast viewing starting on Wednesday, May 25, 2022, at 9:00am EDT.
Session details are as follows
Date: Wednesday, May 25, 2022
Time: 9:00am Eastern Daylight Time (EDT)
Title: Blue Water Vaccines Company Presentation
BWV Participant: Erin Henderson, Chief Business Officer
Webcast Link: https://journey.ct.events/view/1e8775a5-ce07-4395-867a-0cadcc5664e5
BWV's management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at investors@bluewatervaccines.com or contact BWV at (513) 620-4101.
"look forward to exploring the possibility of developing this preliminary research into a new vaccine platform" > This translates into long and winding road. Then comes FDA clinical trials > PHASE I > then Phase II > then Phase III >>>> And finally FDA Approval.
BWV
Imminent run coming, low float is about to pop.
Setting the stage for a powerful move, the only thing that is stopping the run is stop losses being placed, take them off and watch it run when volume comes in. Definitely setting up for an extraordinary move. $15-20 dollars in 2 weeks time frame, anything can happen after that.
This is going to run big, give it 2 weeks easy 15-20 dollars.
10,000 shares now. Will ride this one out.
AH will be interesting
This is trading weird, but someone in control is making alot of money lol?? Imo??
I can tell this is not a very liked ticker by any means, a lot of bag holders, CEO is Hernandez, people seem to hate him a lot. Needless to say, looking for a double and get out.
I was thinking of buying shares in AH. I'll have to do more research.
Huge rug pull, I have been here since the mid 4's. Let's see what happens. Some hedge is playing both sides.
Dropping huge! 5.56 × 5.60 > Best of luck pal!
> Provisional patents have been recently filed for both H3 and influenza B antigens by the Company's licensors and will be used in combination with previously identified H1 epitopes to form the basis for the Company's universal influenza vaccine candidate, BWV-101:
"The large seasonal burden of influenza warrants the development of improved vaccines," said Joseph Hernandez, Chief Executive Officer of Blue Water Vaccines. "This data for H3N2 and influenza B epitopes supports our commitment to develop a vaccine that provides broad protection against all strains and eliminating the need for annual immunization. We are excited to continue our collaboration with The University of Oxford and move forward with this research supporting one of our lead vaccine candidates."
Nice little pop, setting for a big run possibly an IND*O type move or even better LGV*N.
Who the heck is placing market order buys, buy 500 blocks at a time on the ask and place your bids, Robinhood amateurs.
Breakout mode once again this morning.
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
269
|
Created
|
02/18/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |